Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Proof of Concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of OMS906 in Patients With Paroxysmal Nocturnal Hemoglobinuria

NCT05889299 is registered in ClinicalTrials.gov with Omeros Corporation as lead sponsor.

NCT NCT05889299
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05889299 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Proof of Concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of OMS906 in Patients With Paroxysmal Nocturnal Hemoglobinuria
Lead sponsor
Omeros Corporation
Phase
Phase 1
Overall status
Completed
Start date
December 9, 2022
Completion date
November 3, 2025
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

paroxysmal nocturnal hemoglobinuria